Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Blueprint Medicines Corporation

http://www.blueprintmedicines.com/

Latest From Blueprint Medicines Corporation

Blueprint RETreats As It Sells US Gavreto Rights To Rigel

After sales of the RET inhibitor have been commercially disappointing, Blueprint said it is selling US rights to the drug to Rigel for $15m up front and potentially more than $100m in milestones.

Business Strategies Deals

Chinese Domestic Alliances Focus On China-Only Rights As Confidence Grows

Confidence in growing in-house commercial capabilities has recently prompted several Chinese pharmas, including Simcere and 3SBio, to focus on obtaining domestic rights to novel drug assets developed by other China-based biotechs, rather than pursuing international deals.

China Deals

Stock Watch: Oncology Heritage Impedes Roche's Growth

Once a cancer drug powerhouse, Roche’s newer oncology launches were not taking up the slack caused by biosimilar competition to its former blockbusters. Something else was required.

Stock Watch Sales & Earnings

What Next In Oncology?

Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda? 

Cancer Innovation
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
  • Other Names / Subsidiaries
    • Hoyle Pharmaceuticals, Inc.
    • ImmunoCo, Inc.
UsernamePublicRestriction

Register